Aug 2026· Translational Oncology· Vol 72, pp. 102979· 0 citations· 37 references
Medicine
TL;DR
A multimodal signature integrated CT radiomics, deep learning, and pathomics combined to predict progression-free survival in independent cohorts and may support postoperative risk stratification.
Abstract
Highlights • Prognostic tools remain limited for central conventional chondrosarcoma.• A multimodal signature integrated CT radiomics, deep learning, and pathomics.• The signature predicted progression-free survival in independent cohorts.• The signature may support postoperative risk stratification.
We read with great interest the article by Thomas et al. 1 We commend the authors for addressing the clinically important question of preoperative imaging biomarkers for survival prediction in glioblastoma (GBM). However, several methodological, data integrity
Rohini Chaudhari, Varidh Katiyar, Sourabh Zambre· Indian Journal of Radiology...· 0 citations
Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies. This study aimed to identify gene expression signatures that may allow for follow‐up treatment response in CC patients.
Angelo Borges de Melo, F. Queiroz, Carolina Pereira de Souza Melo et al.· Cancer Medicine· 0 citations
We aimed to develop models for predicting programmed death‐ligand 1 (PD‐L1) expression following neoadjuvant chemoradiotherapy (nCRT) in esophageal squamous cell carcinoma (ESCC) using a multifaceted approach that integrates traditional radiomics, deep learning, and machine learning.
Hyun Do Jung, Tae Hoon Lee, Byoung Hyuck Kim et al.· Cancer Medicine· 0 citations
Highlights • Cholangiocarcinoma (CCA) presents a significant clinical challenge with varied subtypes, each requiring tailored treatments.• Early diagnosis of CCA is difficult, leading to poor survival rates, particularly in advanced stages.• Precision medicine is advancing CCA management through targeted therapies based on specific molecular aberrations.• Recent FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.
Augusto Almeida, Joao Manzi, Camila Hoff et al.· Translational Oncology· 0 citations
Magnetic resonance imaging radiomics shows promise in guiding the selection of patients most likely to benefit from the use of immune checkpoint inhibitor therapy in patients with very‐high‐risk, nonmuscle‐invasive bladder cancer. This work arrives at a moment of rapid expansion in bladder‐sparing therapeutics, even as biomarker‐guided patient selection remains conspicuously absent across the field.
Colton H Walker, Navid Jabalameli, S. Rais-Bahrami· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
